What Is Cagrilintide?
Cagrilintide (NN9838) is classified as a metabolic peptide. Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
It is extensively evaluated in laboratory and clinical settings for its potential to drive weight loss, appetite reduction, glycemic control. Researchers target Cagrilintide for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Generally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
How Does Cagrilintide Work?
Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
At the molecular level, Cagrilintide operates through pathways characteristic of the Metabolic class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with weight loss, appetite reduction, glycemic control.
Expected Research Timeline
Weeks 2–4
Measurable weight loss (1-2 lbs/week); improved meal portion control
Months 2–3
10-11% body weight loss at clinical doses; improved glycemic markers
Long-Term
Clinical trials show sustained weight loss through 26+ weeks; CagriSema in Phase 3 trials
What Does the Research Say?
The following are key findings from peer-reviewed studies on Cagrilintide, indexed on PubMed and equivalent databases:
[1]Cagrilintide Phase 2 trial for weight management
Lau et al. (Lancet): Phase 2 RCT showing cagrilintide 4.5mg weekly achieved 10.8% weight loss vs 3.0% placebo at 26 weeks, with acceptable safety profile.
Evidence: strong[2]CagriSema (cagrilintide + semaglutide) Phase 2 results
Frias et al. (Lancet): CagriSema combination achieved 15.6% weight loss at 32 weeks in type 2 diabetes patients — superior to either agent alone.
Evidence: strong[3]Amylin analogs in obesity management: mechanism review
Review of amylin's role in energy homeostasis and why dual amylin-calcitonin receptor agonists like cagrilintide represent a new weight loss mechanism distinct from GLP-1.
Evidence: moderateSafety & Side Effects
Generally well-tolerated in Phase 2 trials. Main side effects are GI-related (nausea, vomiting). Novo Nordisk is developing CagriSema (cagrilintide + semaglutide) as next-gen obesity treatment. Research-only peptide.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~25% of users | moderate |
| Diarrhea | ~10% of users | mild |
| Vomiting | ~8% of users | moderate |
| Injection site reaction | ~5% of users | mild |
| Constipation | ~8% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
Cagrilintide is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Cagrilintide Used?
Route
SubQ
Dose Range
500–4500 mcg
Frequency
Weekly
Cycle
12–24 wk
Timing: Any time, consistent day
Notes: Clinical trial doses: 0.3-4.5mg weekly with dose escalation over 4-8 weeks. Start low (0.3-0.6mg) and increase every 4 weeks to minimize GI side effects.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Cagrilintide vs. Related Compounds
| Compound | Primary Use |
|---|---|
| Cagrilintide(this page) | Weight loss, appetite reduction, glycemic control |
| MOTS-c | Energy, metabolism, fat loss, longevity |
| Semaglutide | Fat loss, appetite control, cardiovascular benefits |
| Tirzepatide | Weight loss, body recomposition, glycemic control |
Where to Source Cagrilintide for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a metabolic peptide. Long-acting amylin analog that activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. Works on a distinct pathway from GLP-1 agonists, making it ideal for combination therapy.
What are the primary research benefits of Cagrilintide?
Published research identifies primary mechanisms targeting: Weight loss, appetite reduction, glycemic control. These findings come from 3+ peer-reviewed studies indexed in our database.
What is the half-life of Cagrilintide?
In published pharmacokinetic data, Cagrilintide demonstrates a half-life of approximately 168 hours.
Is Cagrilintide FDA approved?
Cagrilintide is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Cagrilintide?
Reported side effects in published literature include Nausea (~25% of users), Diarrhea (~10% of users), Vomiting (~8% of users), Injection site reaction (~5% of users), Constipation (~8% of users). Most are classified as moderate in severity.
How is Cagrilintide administered?
In research settings, Cagrilintide is typically administered via SubQ. Clinical trial doses: 0.3-4.5mg weekly with dose escalation over 4-8 weeks. Start low (0.3-0.6mg) and increase every 4 weeks to minimize GI side effects.
Sources
- Cagrilintide Phase 2 trial for weight management. View on PubMed
- CagriSema (cagrilintide + semaglutide) Phase 2 results. View on PubMed
- Amylin analogs in obesity management: mechanism review. View on PubMed